Previous 10 | Next 10 |
Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021 TEL AVIV, Israel , Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and i...
Galmed Pharmaceuticals Ltd. (GLMD) Q3 2020 Earnings Conference Call November 12, 2020 08:30 ET Company Participants Allen Baharaff - President & Chief Executive Officer Yohai Stenzler - Chief Financial Officer Dr. Liat Hayardeny - Chief Scientific Officer Conference Call Participants Stev...
Galmed (GLMD): Q3 GAAP EPS of -$0.32 misses by $0.02.Cash and cash equivalents, restricted cash, short-term deposits and marketable debt securities of $58.7MPress Release For further details see: Galmed EPS misses by $0.02
Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results - Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - PR Newswire TEL AVIV, Israel, Nov. 12, 2020 TEL AVIV, Israel , Nov. 12, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Lt...
Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol Collaboration Seeks to Enhance Response Rate and Identify Biomarker for Treatment of NASH and Fibrosis PR Newswire TEL AVIV and REHOVOT, Israel, Nov. 9, 2020 TEL AVI...
Galmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on Thursday November 12 PR Newswire TEL AVIV, Israel, Nov. 5, 2020 TEL AVIV, Israel , Nov. 5, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD...
Deals and Financings Baidu (BIDU), one of China's major internet/AI companies, is talking with investors about raising $2 billion to fund a new China drug development and diagnostics company. It believes the $2 billion fundraising will take two years to complete. The new company plans to...
TEL-AVIV, Israel and SHANGHAI , Sept. 10, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announces today that they have entered into a research agreement aiming at co...
Galmed Pharmaceuticals (NASDAQ: GLMD ) anf Gannex Pharma, a wholly owned company of Ascletis Pharma Inc. ( OTCPK:ASCLF ) have entered into a research agreement aiming at combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of n...
Introduction It’s closing in on almost 3-years since I first published my initial write-up on Viking Therapeutics ( VKTX ) back in Oct-2017. I’ve had plenty to say about the company since that time, publishing numerous other articles along the way, but more recently I’...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Galmed Pharmaceuticals Ltd. Website: